diarrhea in Extend­ed release study [Outliers]

posted by Researcher101 – Egypt, 2020-09-23 19:53 (206 d 03:08 ago) – Posting: # 21935
Views: 464

Dear All, I'm asking if I have a study on product containing two actives (one IR and the other extended release) and a participant had a diarrhea after Tmax of the IR active and through the Tmax of the XR active. should I exclude the participant from the study? or include him in the XR active statistical calculation and exclude in the IR? :confused:

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,511 registered users;
online 16 (0 registered, 16 guests [including 6 identified bots]).
Forum time: Saturday 23:02 UTC (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5